anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The lipoprotein response will be performed in 15 healthy individuals recruited by newspaper advertisements. Each subject will be their own control, receiving both placebo and teduglutide, administered on separate occasions. A member of the study team will explain the study in detail on visit 1, and if the individual is interested in participating, informed consent will be obtained and preliminary screening will occur on visit 2. On visit 3 \& 4 participants will receive a high fat liquid meal after an overnight fast. Hourly blood samples will be taken for 5 hours, followed by randomized assignment to receive either subcutaneous placebo or teduglutide at visit 3 and the opposite treatment at visit 4. Following the injection, blood samples will be taken every 15 minutes for the first hour and every 30 minutes for the subsequent 3 hours.
PURPOSE:An external drug for the skin, obtained by incorporating 5,8- dihydroxynaphthoquinone and/or an acetoxy derivative thereof as an active constituent, stable to heat and light and capable of accelerating the skin recovery of inflammation, e.g. skin roughening, sunburn, scaled, eczema or burn. CONSTITUTION:An external drug or the skin containing 5,8-dihydroxynaphth oquinone expressed by the formula (R1 and R2 each are independently H or acetyl) and/or an acetoxy derivative thereof as an active constituent. In use, various constituents, generally used in cosmetics, medicines, etc., e.g. water-solu ble constituent, ethanol, oil constituent, e.g. vaseline, surfactant, etc., are incorpo rated and used in the formulation form, e.g. solubilized system such as toilet water, emulsified system such as cream. The amount thereof to be incorporated is 0.001-5wt%, more preferably 0.001-1wt% based on the total amount of the aimed external drug.
About 0,5% of the population in Germany has a chronic hepatitis B virus (HBV) infection. Untreated, chronic HBV infection can progress to liver cirrhosis and hepatocellular carcinoma (HCC). If diagnosed early, antiviral therapy can effectively prevent liver disease progression, but a cure is currently hardly achievable. About 5% of those chronically infected with HBV are also co-infected with the hepatitis D virus (HDV). HBV/HDV co-infection leads to liver cirrhosis in approximately 50% of patients within 5-10 years. Since 2020, the cell entry inhibitor bulevirtide is available as a specific therapy for HBV/HDV co-infection.
Specific skills are taught to youth based on CAMS drivers/case conceptualization of suicidality. Based on our pilot work, the common components of treatment include explicit coaching in skills informed by evidence-based treatments like Dialectical Behavior Therapy (DBT), Cognitive Behavioral Therapy (CBT), and Behavioral Activation (BA). Skills are drawn from the following 3 domains: emotion regulation and crisis survival skills (e.g., paced breathing, use of temperature and exercise to alter mood, Hope Box), behavioral activation strategies (e.g., goal-directed behavior, scheduling of activities, problem-solving) and communication skills (communication around suicidality, validation of self and others, making clear requests/DEAR MAN). Youth assigned to the Ongoing CAMS Intervention condition will receive three, 50-minute sessions that include the interim SSF and driver focused treatment encompassing skills instruction, in-session practice, and assigned homework.
Short bowel syndrome (SBS) leads to severe morbidity and mortality. Intestinal adaptation is crucial in improving outcomes. To understand the human gene pathways associated with adaptation, we perform single-cell transcriptomic analysis of human small intestinal organoids explanted from mice with experimental SBS. We show that transmembrane ion pathways, specifically the transepithelial zinc transport pathway genes SLC39A4 and SLC39A5, are upregulated in SBS. This discovery is corroborated by an external dataset, bulk RT-qPCR, and Western blots. Oral zinc supplementation is shown to improve survival and weight gain of SBS mice and increase the proliferation of intestinal crypt cells in vitro. Finally, we identify the upregulation of SLC39A5 and associated transcription factor KLF5 in biopsied intestinal tissue specimens from patients with SBS. Thus, we identify zinc supplementation as a potential therapy for SBS and describe a xenotransplantation model that provides a platform for discovery in other intestinal diseases.
Canakinumab is a human monoclonal anti-human IL-1β antibody of the IgG1/κ isotype. Canakinumab binds to human IL-1β and neutralizes its activity by blocking its interaction with IL-1 receptors, but it does not bind IL-1α or IL-1 receptor antagonist (IL-1ra).

CAPS refer to rare genetic syndromes generally caused by mutations in the NLRP-3 [nucleotide-binding domain, leucine rich family (NLR), pyrin domain containing 3] gene (also known as Cold-Induced Autoinflammatory Syndrome-1 [CIAS1]). CAPS disorders are inherited in an autosomal dominant pattern with male and female offspring equally affected. Features common to all disorders include fever, urticaria-like rash, arthralgia, myalgia, fatigue, and conjunctivitis. 

The NLRP3 protein is an important component of the inflammasome and regulates the protease caspase-1 and controls the activation of IL-1β. Mutations in NLRP3 result in an overactive inflammasome resulting in excessive release of activated IL-1β that drives inflammation. Still’s disease is a severe autoinflammatory disease, driven by innate immunity by means of proinflammatory cytokines such as IL-1β.

Gout flares are characterized by activation of resident macrophages and infiltrating neutrophils in the joint, and concomitant overproduction of IL-1β resulting in an acute painful inflammatory response. IL-1β production by macrophages is triggered by uric acid (monosodium urate monohydrate) crystals in the joint and surrounding tissue through activation of the NLRP3 inflammasome complex.
Animal Assisted Interactions (AAIs) are interventions that intentionally incorporate animals as part of a therapeutic process to promote human health, learning, and well-being. In general, domestic and farm animals such as dogs, cats, birds, equines, guinea pigs, rabbits, llamas, sheep, goats, and pigs are predominantly featured in AAI programs. Animals can be observed, held, and petted, or more actively integrated into specific therapy activities such as brushing with different tools to encourage range of motion and fine motor coordination. AAIs also promote exercise through tandem walking with the animals. Recent literature indicates that AAI can improve reality orientation and attention span, eliminate the sense of isolation, reduce stress and anxiety, enhance communication, promote positive social interactions, and enhance overall quality of life. The use of AAI in hospitalized children has the potential to engage patients, family members, and healthcare staff in an innovative, holistic approach to recovery.

While additional research is warranted to further explore the potential impact of AAI on a variety of clinically meaningful patient outcomes, the highly technical, fast-paced hospital environment and the immunocompromised health statuses of many acutely ill hospitalized patients greatly limit the exploration of AAI in inpatient settings. A new frontier in animal robotics opens a vast array of opportunities to implement AAI in hospitalized populations. Robot animals may be just as effective as live animals and may provide even more flexibility and tailoring to meet the needs of diverse situations that arise in the hospital. In addition, the infection control risk that live animals pose to hospitalized patients may be significantly lessened.

For this study, the investigators plan to conduct a two-armed randomized controlled trial with repeated measures. Hospitalized pediatric patients will participate in semi-structured, prescriptive physical and occupational therapy sessions on the categories of: 1) speech; 2) balance and endurance; 3) memory; 4) self-esteem; 5) fine motor; 6) sensory stimulation. Intervention group subjects (n=30) will participate in 10-30 minute therapy sessions with Paro, a therapeutic robotic baby harp seal. Control group subjects (n=30) will participate in 10-30 minute therapy sessions without Paro.
The abdominal binder is worn from immediately after the operation and continuously for 7 days, night and day. The belts are standard elastic belts (ostomy belts) from "ETO garments©" with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done before the operation by waist measurement according to the recommendation from the company.
ZYVOX I.V. Injection is supplied in single-use, ready-to-use infusion bags. Parenteral drug products should be inspected visually for particulate matter prior to administration. Check for minute leaks by firmly squeezing the bag. If leaks are detected, discard the solution, as sterility may be impaired . Keep the infusion bags in the overwrap until ready to use. Store at room temperature. Protect from freezing. ZYVOX I.V. Injection may exhibit a yellow color that can intensify over time without adversely affecting potency. 

ZYVOX I.V. Injection should be administered by intravenous infusion over a period of 30 to 120 minutes. Do not use this intravenous infusion bag in series connections. Additives should not be introduced into this solution. If ZYVOX I.V. Injection is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each product. 

If the same intravenous line is used for sequential infusion of several drugs, the line should be flushed before and after infusion of ZYVOX I.V. Injection with an infusion solution compatible with ZYVOX I.V. Injection and with any other drug(s) administered via this common line.
Participants allocated to the Control Exercise Group will participate in 8 total exercise sessions (2x per week for 4 weeks). Exercise sessions will include two exercise modalities 1)seated rowing ergometer and 2) dumbbell deadlifts. Exercise intensity will be individualized based upon preliminary testing with rowing at 80% maximal Watts, and deadlifts at 60% of one-repetition maximum.
A doctor health monitoring system based on a medical apparatus (1). The system comprises the medical apparatus (1), a detecting system (2), a control system (3) and an artificial intelligence system (14). The detecting system (2) is used for detecting health indices of a doctor and transmitting detected data to the control system (3). The control system (3) and the artificial intelligence system (14) are integrated into the medical apparatus (1), and the control system (3) is used for transmitting received data to a display device (11) for display. The artificial intelligence system (14) is used for carrying out analysis and research according to data in a cloud server (12), so as to acquire diagnosis accuracy of the health indices and predict the health condition of the doctor. In the present system, the detecting system (2) capable of detecting the health indices of a doctor is connected to the medical apparatus (1), so that the health indices of the doctor may be detected in real time, the body health condition of the doctor may be learned, and conditions such as the doctor having low blood sugar during a diagnosis process may be resolved in time, thereby ensuring a smooth treatment process.
Western diet (WD) consumption during early life developmental periods is associated with impaired memory function, particularly for hippocampus (HPC)-dependent processes. We developed an early life WD rodent model associated with long-lasting HPC dysfunction to investigate the neurobiological mechanisms mediating these effects. Rats received either a cafeteria-style WD (ad libitum access to various high-fat/high-sugar foods; CAF) or standard healthy chow (CTL) during the juvenile and adolescent stages (postnatal days 26-56). Behavioral and metabolic assessments were performed both before and after a healthy diet intervention period beginning at early adulthood. Results revealed HPC-dependent contextual episodic memory impairments in CAF rats that persisted despite the healthy diet intervention. Given that dysregulated HPC acetylcholine (ACh) signaling is associated with memory impairments in humans and animal models, we examined protein markers of ACh tone in the dorsal HPC (HPCd) in CAF and CTL rats. Results revealed significantly lower protein levels of vesicular ACh transporter in the HPCd of CAF vs. CTL rats, indicating chronically reduced ACh tone. Using intensity-based ACh sensing fluorescent reporter (iAChSnFr) in vivo fiber photometry targeting the HPCd, we next revealed that ACh release during object-contextual novelty recognition was highly predictive of memory performance and was disrupted in CAF vs. CTL rats. Neuropharmacological results showed that alpha 7 nicotinic ACh receptor agonist infusion in the HPCd during training rescued memory deficits in CAF rats. Overall, these findings reveal a functional connection linking early life WD intake with long-lasting dysregulation of HPC ACh signaling, thereby identifying an underlying mechanism for WD-associated memory impairments.
New process is claimed for prodn. of microcapsules by emulsifying a solution of a film-forming polymer and of the substance to be encapsulated in a liq. medium with which it is immiscible, and treating the emulsion with a liq. which does not dissolve the polymer but is miscible with the solvent. In the new process, the ratio of non-solvent liquid to emulsion is 1:1 to 10:1 v/v, and the emulsion is slowly added to the non-solvent liquid. Used for microencapsulation of substances such as pharmaceuticals, plant protection agents, microbial cells, adsorbents, pigments and dyes. The process can be used e.g. for the prodn. of prolonged release formulations of plant protection agents or for the immobilisation of enzymes. The new process reverses the procedure of DE 2264074 (addition of non-solvent to emulsion) and thus minimises problems such as flocculation of the polymer and clumping of the microcapsules.
EQU-001 is a Phase 1 randomized, placebo-controlled, double-blind SAD/MAD study to evaluate safety, tolerability, PK, and high-fat food effects on EQU-001. Eight healthy adult participants will be enrolled in each of up to 5 cohorts in both the SAD and MAD portions of the study (10 mg, 20 mg, 40 mg, 80 mg, and 120 mg). The participants will be randomized 3:1, drug to placebo. The MAD dosing is for 14 days, to include a period of time where the study drug will be at steady-state. Eight participants from the SAD study (the 40 mg dose cohort or the MTD dose cohort, whichever dose is lower) will also complete a fed portion of the study.

This study of EQU-001 will provide baseline safety, tolerability, PK, and food effect data in healthy individuals and aims to identify drug-specific DLTs and an MTD. The PK component will characterize the PK of EQU-001 to inform dosing and may help to correlate exposures with any DLTs or other treatment-related AEs. The food effect component will characterize the effect of a high-fat meal on EQU-001 kinetics and exposure.
Identification of a safe, effective treatment for individuals with mild or moderate COVID-19 that prevents disease progression and reduces hospitalization would reduce the burden on the health system. High dose hydroxychloroquine is being evaluated for SARS-CoV-2 prevention and COVID-19 disease treatment, but has a high risk of a number of potentially severe adverse events. Recent evidence has indicated that the broad-spectrum macrolide azithromycin may have some activity against coronaviruses. Here we propose an individually-randomized, placebo-controlled trial to determine the efficacy of a single dose of azithromycin for prevention of COVID-19.

Potential participants will undergo remote eligibility screening with study staff prior to enrollment. Upon determination of eligibility and signing electronic informed consent documents, participants will be emailed baseline study forms and will be mailed their randomized study treatment. At the end of the study (21 days), participants will be emailed a final study questionnaire. Note that there will no contact between study staff and participants in this trial, minimizing risk of infection spread.
This group will receive five daily sessions of 2mA, current for 30 seconds tDCS. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage). In addition, the following test will performed: X-Rays, Walking Test, Assessment of Physical Performance, Assessment of Sensitivity to Heat, Assessment of Sensitivity to Pressure, Assessment of Sensitivity to Mechanical Stimulation, Assessment of balance, chair stand, Assessment of conditioned pain modulation, and gait speed and Blood test.
The invention relates to flavones separated and purified from shepherd's purse. The method comprises the following steps: ethanol ultrasonic extraction, solvent extraction, silica gel column chromatography eluting separation, resin column adsorption, silica gel column chromatography eluting separation, vacuum concentration, vacuum drying and the like. The name of the separated flavones is 2-(3,4-dimethoxyphenyl)-5-(hydroxymethyl-7-O-beta-D-glucosyl-4H-chromene-4-one. The raw material, which is the medicinal and edible shepherd's purse, has abundant sources and is cheap and accessible. The prepared 5-hydroxymethyl new flavones have novel structure, have obvious effect of inhibiting tumor cell proliferation, and can be used as a cell proliferation inhibitor or antitumor agent for antitumor research. The flavones have favorable development and utilization values, and lay foundation for research and development of clinical drugs for preventing and treating tumors in future.
The invention provides a specific medicine for controlling the hiccup disease. The specific medicine is last-year rice straws and has the middle warmer warming, deficiency tonifying and diaphragm spasm preventing functions. The specific medicine has substantial treatment effects on hiccups generated after intractable or prolonged diseases and serious diseases. The preparation method of the last-year rice straws concretely comprises the following steps: straws residual in the field after the rice harvesting are put in a water storage field through the winter, are taken out in the next year, and are cleaned to remove soil in order to obtain the last-year rice straws for later use. 1000g of the last-year rice straws is boiled in 3000g of water for 0.5h, the obtained decoction is drunk after the decoction is warm or cold, the drinking amount at the first time is relatively lager, and then the decoction is drunk as a tea. The hiccup disease can be cured after taking for 1-2 days.
The invention provides paris polyphylla polysaccharide with immunocompetence and a composition and application thereof, and belongs to the technical field of active polysaccharide. The main chain of the paris polyphylla polysaccharide RP66-19 is glucan connected with alpha (1 → 4), glucose on the side chain is connected with the main chain by (1 → 6), and monosaccharide composition is glucose with the molecular weight of 2380 Da. Is prepared from paris polyphylla rhizome through drying, pulverizing, decolouring, defatting, hot water extracting, alcohol depositing, starch detecting and treating, gel column chromatography and ion exchange column chromatography. Analyzing and confirming the structure of Yunnan rhizoma paridis polysaccharide RP66-19 by high performance liquid chromatography, mass spectrometry, gas chromatography, one-dimensional and two-dimensional nuclear magnetic spectrum, ultraviolet and infrared spectroscopy and other methods. The paris polyphylla polysaccharide RP66-19 can promote the release of NO and cytokines (IL-10 and IL-6) from mouse mononuclear macrophage leukemia cells RAW264.7, and enhance the phagocytic capacity of macrophages, and has certain correlation with concentration. The paris polyphylla polysaccharide RP66-19 and the composition thereof can be used as important sources for developing immunoregulation medicaments and functional foods.
Currently, chronic hepatitis B virus infection is still one of the most serious public health problems in the world. Though current strategies are effective in controlling infection and slowing down the disease process, it remains a big challenge to achieve a functional cure for chronic hepatitis B in a majority of patients due to the inability to clear the cccDNA pool. The mammalian target of rapamycin (mTOR) integrates nutrition, energy, growth factors, and other extracellular signals, participating in gene transcription, protein translation, ribosome synthesis, and other biological processes. Additionally, mTOR plays an extremely important role in cell growth, apoptosis, autophagy, and metabolism. More and more evidence show that HBV infection can activate the mTOR pathway, suggesting that HBV uses or hijacks the mTOR pathway to facilitate its own replication. Therefore, mTOR signaling pathway may be a key target for controlling HBV infection. However, the role of the central cytokine mTOR in the pathogenesis of HBV infection has not yet been systematically addressed. Notably, mTOR is commonly activated in hepatocellular carcinoma, which can progress from chronic hepatitis B. This review systematically summarizes the role of mTOR in the life cycle of HBV and its impact on the clinical progression of HBV infection.
The investigators will review the hospital records at the investigational site for SCAD events having occurred over the last 5 years. All SCAD patients aged ≥18 years, not presenting atherosclerotic or iatrogenic coronary dissection will be informed about the SwissSCAD study by phone and will be given at least one week to decide if they wish to participate. We plan to include 500 patients in the retrospective arm.
Among the 2 million amputees in the United States, 60% to 90% will experience phantom limb pain (PLP). Managing PLP presents challenges with current evidence-based pharmacological and interventional therapies yielding varied results. In recent years, advancements in neuromodulation, such as scrambler therapy (ST), have demonstrated effectiveness in addressing various chronic and neuropathic pain syndromes. In terms of PLP, however, cases have been limited. This case highlights further evidence supporting ST for PLP over 5 years. Furthermore, we provide clinical images of the amputation with ST electrodes as well as a 5-year record of pain and Edmonton Symptom Assessment System scores.
Topical composition (A), contains as active ingredient, one or more fragments (I) of hyaluronate with molecular weight 50-750 kD. ACTIVITY : Dermatological. MECHANISM OF ACTION : (I) increases the number of proliferating cells, particularly fibroblasts, in the epidermis and dermis, so induce epidermal thickening. A standard cosmetic vehicle contained 0.2 % hyaluronate fragments of molecular weight 50-250 kD and was applied twice daily to the skin of SKH1 hairless mice. After an unspecified treatment time, epidermal thickness and the number of proliferating cells were determined. The mean thickness was 0.32 mm (compare 0.07 mm in controls) and the number of cells (per microscope field) was 257 compared with 96 in controls. Also the mean number of proliferating cells (positive for the marker Ki67; per field) was 96 in the epidermis and 5 in the dermis; compare 26 and 0.95 in controls.